Tafluprost

Summary

Tafluprost (CHEMBL1963683) is an approved small-molecule prostaglandin receptor agonist (ATC S01EE05) targeting PTGFR; indicated across 3 conditions including open-angle glaucoma and ocular hypertension.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S01EE05
• Targets: 1 (PTGFR)
• Indications: 3 conditions
• Clinical trials: 18
• Chemistry: 452.5 Da · C25H34F2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1963683
Name	Tafluprost
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9868491
ChEBI	CHEBI:66899
ATC	S01EE05
Molecular formula	C25H34F2O5
Molecular weight	452.5
InChIKey	WSNODXPBBALQOF-VEJSHDCNSA-N

SMILES: CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(COC2=CC=CC=C2)(F)F)O)O

IUPAC name: propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate

ChEBI definition: A prostaglandin Fα that is prostaglandin F2α in which the carboxylic acid function has been converted to the corresponding isopropyl ester and the 3-hydroxy-1-octenyl side-chain is substituted by 3,3-difluoro-4-phenoxybut-1-enyl. Used for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Pharmacological roles (ChEBI): prostaglandin receptor agonist.

Also known as: AFP-168, MK-2452, Saflutan, Tafluprost, Zioptan, TAFLUPROST, tafluprost

Patent coverage: 496 distinct patent families (1,305 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGFR	FP receptor	Agonist		0%	P43088

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Thromboxane A2 receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): PTGFR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Prostanoid ligand receptors	1	PTGFR
G alpha (q) signalling events	1	PTGFR

Dominant GO biological processes

GO term	Targets
inflammatory response	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
positive regulation of cytosolic calcium ion concentration	1
parturition	1
positive regulation of cell population proliferation	1
positive regulation of gene expression	1
response to estradiol	1
response to lipopolysaccharide	1
negative regulation of apoptotic process	1
cellular response to prostaglandin D stimulus	1
signal transduction	1
response to lipid	1

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
open-angle glaucoma	4	MONDO:0005338	EFO:0004190
ocular hypertension	4	MONDO:0006875	EFO:1001069
glaucoma	4	MONDO:0005041	MONDO:0005041

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE4	8
PHASE3	7
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00966940	PHASE4	COMPLETED	Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
NCT01162603	PHASE4	COMPLETED	Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)
NCT01369771	PHASE4	COMPLETED	The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma
NCT02802137	PHASE4	COMPLETED	24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
NCT03104621	PHASE4	COMPLETED	Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients
NCT03204487	PHASE4	COMPLETED	A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness
NCT03612817	PHASE4	COMPLETED	Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing
NCT05299593	PHASE4	UNKNOWN	24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.
NCT00596791	PHASE3	COMPLETED	Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
NCT00918346	PHASE3	COMPLETED	Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation
NCT01026831	PHASE3	COMPLETED	Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
NCT01087671	PHASE3	COMPLETED	Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops
NCT01292460	PHASE3	COMPLETED	Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
NCT01306461	PHASE3	COMPLETED	Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations
NCT01433900	PHASE3	UNKNOWN	Switching From Preserved to Preserved-free Treatments for Glaucoma.
NCT01654484	PHASE1/PHASE2	COMPLETED	A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
NCT04737928	Not specified	COMPLETED	Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
NCT04828057	Not specified	COMPLETED	Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

13 molecules share ≥1 primary target. Top 13 by shared-target count:

Molecule	Source	Status	Shared targets
DINOPROST	ChEMBL + PubChem	Phase 4 (approved)	PTGFR
DINOPROSTONE	ChEMBL + PubChem	Phase 4 (approved)	PTGFR
LAROPIPRANT	ChEMBL	Phase 4 (approved)	PTGFR
SEPETAPROST	ChEMBL	Phase 3	PTGFR
CLOPROSTENOL	ChEMBL + PubChem	Phase 2 (approved)	PTGFR
EBOPIPRANT	ChEMBL	Phase 2	PTGFR
FLUPROSTENOL	ChEMBL	Phase 2	PTGFR
Belzutifan	PubChem	Approved	PTGFR
Bimatoprost	PubChem	Approved	PTGFR
Grapiprant	PubChem	Approved	PTGFR
Latanoprost	PubChem	Approved	PTGFR
Latanoprostene Bunod	PubChem	Approved	PTGFR
Nitroglycerin	PubChem	Approved	PTGFR